The purpose of this paper is to describe some methods for analyzing and summarizing adverse event rates from clinical trials, emphasizing, in particular, serious adverse drug events and their time of occurrence, and the impact of differential subject exposure and pretreatment status on the estimation of rates.
Idanpaan-Heikkila Juhana: A review of safety information obtained from Phase I-II and Phase III clinical investigations of sixteen selected drugs. U.S. Department of Health and Human Services, Office of New Drug Evaluation, National Center for Drugs and Biologics, June, 1983.
3.
GiffordLMAeugleMEMyersonRMTannenbaumPJ: Cimetidine postmarket outpatient surveillance program: Interim Report on Phase I. JAMA1980; 243:1532–1535.
4.
GroelJTTadrosSSDreslinskiGRJenkinsAC: Long-term antihypertensive therapy with Captopril. Hypertension1983: 5 (suppl III) No 5, 145–151.
5.
PeckAW: Incidence of seizures during treatment with tricyclic antidepressant drugs and Bupropion. J Clin Psychiatry1983; 44: No 5, 197–201.
6.
RossiAC: Discovery of new adverse drug reactions. A review of the Food and Drug Administration's spontaneous reporting system. JAMA252: No 8, 1030–1033.
7.
SK&F Lab Co Promotional Brochure TG31 Tagamet Post-Marketing Surveillance Program Initial and Six Month Follow-Up Reports May, 1981.
